1529 Treffer:
41.
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (e
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Pleuramesotheliom
Datum: 2026-05-09
42.
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Me
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
43.
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
44.
A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
45.
A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Adolescent and Adult Patients with Soft-tissue and Bone Sarcoma
NCT Heidelberg » Für Ärzte » Studien » Sarkome » Weichteilsarkome
Datum: 2026-05-09
46.
Eine unverblindete, multizentrische First-in-Human-Studie der Phase 1/2 zu Sicherheit, Verträglichkeit, Pharmakokinetik und Anti-Tumoraktivität von TPX-0005 bei Patienten mit fortgeschrittenen soliden Tumoren mit ALK-, ROS1- oder NTRK1-3-Rearrangements
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
47.
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivant
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
48.
Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
49.
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
50.
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09